东方生物(688298) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥239,378,629.93, an increase of 58.92% compared to the same period last year[2] - Net profit attributable to shareholders was -¥110,548,767.87, a decrease of 3.13% year-on-year[2] - Basic earnings per share for the year-to-date were -¥1.32, a decrease of 267.98% compared to the previous year[3] - The company experienced a 262.17% decrease in net profit attributable to shareholders from the beginning of the year to the reporting period[6] - The net profit for the third quarter of 2024 was -274,227,549.60 RMB, compared to -67,266,359.19 RMB in the same period of 2023, indicating a significant increase in losses[19] - Operating profit for the third quarter was -282,546,252.62 RMB, a decline from -44,437,855.43 RMB year-over-year[19] - The company reported a total comprehensive loss of -291,781,782.68 RMB for the third quarter, compared to -42,388,332.53 RMB in the same quarter of 2023[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,234,404,013.88, down 8.47% from the end of the previous year[3] - The company's total assets decreased to ¥8,234,404,013.88 from ¥8,995,951,150.74[17] - The total liabilities decreased to ¥1,183,176,692.28 from ¥1,446,223,002.71, indicating improved financial health[16] - The company's equity attributable to shareholders was ¥6,880,382,859.03, down 7.47% from the previous year[3] - The company's equity attributable to shareholders decreased to ¥6,880,382,859.03 from ¥7,436,071,401.35, reflecting changes in retained earnings[17] - Short-term borrowings decreased to ¥186,735,657.38 from ¥198,221,896.67, showing a reduction in reliance on debt[16] Cash Flow - Cash flow from operating activities for the year-to-date increased by 77.33% compared to the previous year[7] - The cash flow from operating activities showed a net outflow of -367,152,854.58 RMB, an improvement from -1,619,675,103.24 RMB in the previous year[21] - The company reported a financial expense of -¥45,920,433.50, a significant improvement from -¥252,109,103.42 in the previous year, indicating better financial management[18] - The net cash flow from financing activities was -374,987,236.57, a significant decrease compared to 35,322,755.53 in the previous period[22] - Cash and cash equivalents at the end of the period totaled 1,942,768,528.39, down from 4,844,939,391.44 at the beginning of the period[22] - The net decrease in cash and cash equivalents was -985,834,813.78, compared to -1,711,620,452.84 in the previous period[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10[8] - The company’s major shareholders include Anji Fulanglai Import and Export Trade Co., Ltd., holding 39.31 million shares, representing 19.50% of the total shares[10] - The top ten unrestricted shareholders collectively hold a significant portion of the company's shares, with the largest shareholder controlling 39.31 million shares[10] Research and Development - R&D expenses totaled ¥63,579,055.71, accounting for 26.56% of revenue, a decrease of 16.19% compared to the previous year[3] - Research and development expenses rose to ¥209,881,229.54, compared to ¥188,135,533.21 in the previous year, indicating a focus on innovation[18] Market and Product Development - The company achieved FDA De Novo certification for its Healgen Rapid Check COVID-19/flu A&B Antigen Test on October 7, 2024, marking it as the first OTC testing product to receive this certification in the U.S.[13] - The company has established a strategic focus on expanding its market presence in the U.S. for respiratory testing products[13] - The company plans to continue monitoring the market demand for its newly certified products in the U.S. and actively promote sales[13] Share Buyback and Financial Management - The company completed a share buyback program, repurchasing 8.4036 million shares, which is 4.17% of the total share capital, with a total expenditure of approximately RMB 277 million[13] - The company’s share buyback was approved with a budget of between RMB 250 million and RMB 300 million, aimed at employee stock ownership plans or equity incentives[13] Other Financial Metrics - The company reported a total of ¥32,035,741.30 in non-recurring gains and losses for the current period[5] - Total operating revenue for the first three quarters of 2024 reached ¥657,613,863.02, a slight increase from ¥652,171,856.12 in the same period of 2023[18] - Total operating costs increased significantly to ¥1,015,757,409.45 from ¥718,719,790.87 year-on-year[18] - The company reported an increase in accounts receivable, with notes receivable rising to RMB 1.80 million from RMB 1.57 million, an increase of 14.0%[14] - Accounts receivable increased to ¥271,051,469.49 from ¥206,163,074.65, reflecting a growing customer base[15] - Inventory levels rose to ¥427,260,228.20, up from ¥346,775,187.97, suggesting increased production or stockpiling[15] - Interest income decreased to 83,735,447.92 RMB from 158,298,097.02 RMB year-over-year, reflecting a decline of approximately 47%[19] - The company reported a total of 4,996,672.21 RMB in other income, down from 8,465,436.48 RMB in the previous year, indicating a decrease of about 41%[19] - The company distributed dividends and interest payments totaling 10,939,543.43, down from 390,641,397.99 in the previous period[22] Accounting Changes - The company has adopted new accounting standards starting from 2024, which may affect the financial statements[22]